A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs R 835 Rigel Pharmaceuticals (Primary)
- Indications Arthritis; Gout; Immunological disorders; Multiple sclerosis; Psoriasis
- Focus Adverse reactions
- 23 Oct 2019 Status changed from recruiting to completed, according to a Rigel Pharmaceuticals media release.
- 06 Aug 2019 According to a Rigel Pharmaceuticals media release, data from this study is expected in the second half of 2019.
- 02 Jul 2018 New trial record